Record Revenue and Full Enrollment: RenovoRx Delivers on All Three Milestones
Commercial execution: from concept to compounding revenue
RenovoRx’s second quarter of 2026 marked a decisive step in its evolution from a clinical-stage idea to a scaling commercial business. Management had telegraphed three milestones: revenue growth, commercial momentum, and expansion beyond locally advanced pancreatic cancer (LAPC). On all three, the company overdelivered.
The headline number was “record revenue quarter, our strongest to date” — Shaun R. Bagai, Chief Executive Officer · 2026-08-12 — $909,000, up 61% sequentially and 115% year over year. That single quarter represented roughly 83% of all 2025 revenue. The driver was a growing roster of active commercial cancer centers, which rose 30% in one quarter from 16 to 21, with a robust pipeline of 42 additional centers in various stages of evaluation. CEO Shaun Bagai pointed to repeat ordering as the clearest indicator of physician satisfaction, and management highlighted a "compounding effect" as each new center adds recurring demand. The customer funnel — active sites plus pipeline — expanded 31% sequentially to 63 centers, and CFO Mark Voll noted that the economics remain healthy with gross margin holding near 84%. This is a stark departure from the company's first commercial quarter in Q1 2025, when “revenue from RenovoCath exceeded our internal expectations to approximately $200,000” — Shaun Bagai · 2025-05-15.Over the past several quarters, we set out 3 milestones for RenovoRx. And this quarter, we delivered on all 3.
Beyond LAPC: a physician-driven expansion into sarcoma
For the first time, RenovoCath was used commercially to treat a sarcoma patient, a milestone that validates the platform’s broader potential. “For the first time, a treating physician chose RenovaCath to deliver therapy to a patient with a different solid tumor.” — Shaun R. Bagai, Chief Executive Officer · 2026-08-12 Chief Medical Officer Ramtin Agah explained that the physician, already experienced with TAMP in pancreatic cancer, adapted the device to a difficult-to-reach sarcoma. This opens the door to a solid tumor franchise beyond the initial LAPC focus. The company sees TAMP as a "fourth option" beyond surgery, radiation, and systemic chemo — a claim reinforced by emerging publications from Moffitt Cancer Center and Hackensack Meridian Health. The commercial infrastructure built over the past several quarters is now showing its leverage: a lean sales team, strong repeat demand, and physician-to-physician advocacy.
Clinical cornerstone: TIGeR PaC reaches full enrollment
The Phase 3 TIGeR-PaC trial, evaluating intra-arterial gemcitabine delivered via RenovaCath versus systemic chemotherapy, achieved full enrollment on August 7, 2026. “We believe TAMP, enabled by RenovaCath, represents a fourth option.” — Ramtin Agah, Chief Medical Officer, Executive Chair and Founder · 2026-08-12 Data monitoring confirms 78 of the 86 required events have occurred, and top-line results are expected in the back half of 2027. Management frames the trial as "important background" to the commercial story, but a positive readout would be a significant value driver, affecting both physician adoption and reimbursement. The trial sites are expected to convert to commercial customers, adding to second-half revenue. The company's prior commentary emphasized the importance of the side-effect profile in driving physician interest; as Shaun noted in the prior quarter, “the physicians really are looking at the side effect profile as the largest driver” — Shaun Bagai, Chief Executive Officer · 2026-05-14 — a theme that now extends to sarcoma and beyond.
Financials: scaling revenue, disciplined burn, raised guidance
The company raised its 2026 revenue guidance to a range of $3.75–$4.25 million, implying 241%–286% growth over 2025. “we are raising and tightening the range of our full year 2026 revenue guidance to a range of $3.75 million to $4.25 million” — Mark Voll, Chief Financial Officer · 2026-08-12 Operating loss improved on an adjusted basis, and management believes a quarterly run rate of ~$5 million would achieve break-even, targeted for Q4 2027. Cash and equivalents stood at $9.5 million, with runway into the second half of 2027. Cash runway fell to 3.3 quarters from 5.4 a year ago, reflecting disciplined deployment into commercial infrastructure and the trial. The trajectory is consistent with management’s earlier statements that they are "well-suited in operating expense levels as we ramp revenue." Looking at the cumulative evidence, RenovoRx is no longer a binary event bet but a scaling commercial business with a pivotal catalyst in the pipeline. The record revenue, expanding center base, and first expansion beyond LAPC—all three milestones delivered—point to a company that is executing on its plan. The raised guidance and the path to break-even reinforce this narrative. The key risk remains the timing of the TIGeR-PaC readout and continued execution on site activation, but the quarter’s results provide a strong foundation for the second half of the year.